VIVOSIM LABS, INC. filed for an IPO. They’re a biotech platform focused on simulating human biology. The headline metric: they’re aiming to raise up to $17.25M.

On financials: the filing doesn’t detail historical revenue or profit yet, which is common for early-stage biotechs entering the public markets. A key risk flagged: management has broad discretion over net proceeds. That means investors are betting heavily on the team’s capital allocation instincts. The bottom line: a speculative biotech play where immediate dilution is a stated risk. This is a story about platform potential, not proven financials.

On financials: the filing doesn’t detail historical revenue or profit yet, which is common for early-stage biotechs entering the public markets.